ATE362994T1 - Verwendung von dna-pk - Google Patents

Verwendung von dna-pk

Info

Publication number
ATE362994T1
ATE362994T1 AT99937188T AT99937188T ATE362994T1 AT E362994 T1 ATE362994 T1 AT E362994T1 AT 99937188 T AT99937188 T AT 99937188T AT 99937188 T AT99937188 T AT 99937188T AT E362994 T1 ATE362994 T1 AT E362994T1
Authority
AT
Austria
Prior art keywords
protein kinase
dependent protein
dna dependent
subunit
dna
Prior art date
Application number
AT99937188T
Other languages
English (en)
Inventor
Gloria Li
Paul Burgman
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE362994T1 publication Critical patent/ATE362994T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/121—Hammerhead

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT99937188T 1998-06-30 1999-06-30 Verwendung von dna-pk ATE362994T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9118198P 1998-06-30 1998-06-30

Publications (1)

Publication Number Publication Date
ATE362994T1 true ATE362994T1 (de) 2007-06-15

Family

ID=22226489

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99937188T ATE362994T1 (de) 1998-06-30 1999-06-30 Verwendung von dna-pk

Country Status (9)

Country Link
EP (1) EP1090146B1 (de)
JP (1) JP2002519010A (de)
AT (1) ATE362994T1 (de)
AU (1) AU5206899A (de)
CA (1) CA2332179C (de)
DE (1) DE69936141T2 (de)
ES (1) ES2288318T3 (de)
HK (1) HK1036483A1 (de)
WO (1) WO2000000644A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9907687D0 (en) 1999-04-01 1999-05-26 Kudos Pharm Ltd Assays methods and means
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
AU2001221607A1 (en) 2000-11-20 2002-05-27 Ecole Polytechnique Federale De Lausanne (Epfl) Endosseous implant
EP1436406A4 (de) * 2001-09-24 2004-10-13 Blood Ct Res Foundation Verfahren zur modulation oder untersuchung des ku70-spiegels in zellen
EP1660473A2 (de) 2003-03-24 2006-05-31 Luitpold Pharmaceuticals, Inc. Xanthone, thioxanthone und acridinone als dna-pk-hemmer
WO2005089757A1 (en) * 2004-03-15 2005-09-29 Sunesis Pharmaceuticals, Inc. Sns-595 and methods of using the same
GB201022007D0 (en) * 2010-12-24 2011-02-02 Imp Innovations Ltd DNA-sensor
JP7492687B2 (ja) 2017-07-30 2024-05-30 清華大学 Ｄｎａ－ｐｋｃｓを阻害するための薬物治療

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641754A (en) * 1994-01-10 1997-06-24 The Board Of Regents Of The University Of Nebraska Antisense oligonucleotide compositions for selectively killing cancer cells
AU6906396A (en) * 1995-08-30 1997-03-19 Arch Development Corporation Methods and compositions including dna damaging agents and tyrosine kinase inhibitors or activators
US5955644A (en) * 1996-08-08 1999-09-21 M.D. Anderson Cancer Center Ku deficient cells and non-human transgenic animals

Also Published As

Publication number Publication date
HK1036483A1 (en) 2002-01-04
DE69936141D1 (de) 2007-07-05
WO2000000644A1 (en) 2000-01-06
AU5206899A (en) 2000-01-17
CA2332179A1 (en) 2000-01-06
EP1090146A4 (de) 2002-04-17
EP1090146B1 (de) 2007-05-23
JP2002519010A (ja) 2002-07-02
DE69936141T2 (de) 2008-01-31
CA2332179C (en) 2011-06-28
EP1090146A1 (de) 2001-04-11
ES2288318T3 (es) 2008-01-01

Similar Documents

Publication Publication Date Title
Kilani et al. RNase P ribozymes selected in vitro to cleave a viral mRNA effectively inhibit its expression in cell culture
Goodchild Enhancement of ribozyme catalytic activity by a contiguous oligodeoxynucleotide (facilitator) and by 2′-O-methylation
Branlant et al. U2 RNA shares a structural domain with U1, U4, and U5 RNAs.
Kassavetis et al. Pausing and termination of transcription within the early region of bacteriophage T7 DNA in vitro.
Adams et al. Control of mRNA stability in chloroplasts by 3′ inverted repeats: effects of stem and loop mutations on degradation of psb A mRNA in vitro
Zhou et al. In Vitro Selection of External Guide Sequences for Directing RNase P-mediated Inhibition of Viral Gene Expression* 210
EP1650298A1 (de) Oligonukleotidgeneratoren basierend auf Promotoren der RNS Polymerase III des Typs U6
Kuwabara et al. tRNAVal-heterodimeric maxizymes with high potential as geneinactivating agents: simultaneous cleavage at two sites in HIV-1 Tat mRNA in cultured cells
ATE280772T1 (de) Antisense oligonukleotidmodulation der raf genexpression
ATE151467T1 (de) Durch modifikationen an der 3'-terminalen phosphodiesterbindung stabilisierte dna moleküle, ihre verwendung als nukleinsäuresonden sowie als therapeutische mittel zur hemmung der expression spezifischer zielgene
ATE216705T1 (de) Antisense-oligonukleotidmodulation der raf- genexpression
DK1053313T3 (da) Optimerede antisense oligonucleotider komplementære til DNA methyltransferase-sekvenser
Sarih-Cottin et al. Preferential interaction of human immunodeficiency virus reverse transcriptase with two regions of primer tRNALys as evidenced by footprinting studies and inhibition with synthetic oligoribonucleotides
ATE362994T1 (de) Verwendung von dna-pk
Marsich et al. Evidence for a HeLa nuclear protein that binds specifically to the single-stranded d (CCCTAA) n telomeric motif
Miller Development of antisense and antigene oligonucleotide analogs
Roy et al. Delta ribozyme has the ability to cleave in trans an mRNA
Guschina et al. Recognition of specific and nonspecific DNA by human lactoferrin
Gimple et al. In vitro and in vivo processing of cyanelle tmRNA by RNase P
Flynn-Charlebois et al. A single metal ion plays structural and chemical roles in an aminoacyl-transferase ribozyme
EP1832663A3 (de) Verwendungen von DNA-PK
Sabariegos et al. Catalytic RNase P RNA from Synechocystis sp. cleaves the hepatitis C virus RNA near the AUG start codon
Patutina et al. Search for oligonucleotides selectively binding oncogenic miR-21
ATE455850T1 (de) Contortrostatin(cn) sowie verfahren zu seiner verwendung in der prävention von metastasen und anderer zustände
Hori et al. The catalytic RNA of RNase P from Escherichia coli cleaves Drosophila 2S ribosomal RNA in vitro: a new type of naturally occurring substrate for the ribozyme

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties